ArticleHepatology communications2026
Targeted community screening in areas of high socioeconomic deprivation enhances the detection of liver fibrosis.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundRisk-factor-based community screening has been used to identify early liver disease. Risk-factor prevalence and liver-related outcomes are significantly affected by socioeconomic deprivation. However, the impact on targeted community screening is unknown. We evaluated the influence of deprivation on fibrosis detection within a population screening pathway.
methodsA total of 1613 patients were assessed using 2 pathways: Proactive case finding at 7 primary care practices (PCPs) and a comparator standard-of-care pathway. Individuals with specific risk factors were identified: obesity (BMI >30 kg/m2), type 2 diabetes, alcohol consumption >400/>280 g/week in males/females, respectively, coding for steatosis and ALT >50/>35 IU/mL in males/females, respectively. Liver stiffness measurement (LSM) ≥8.0 kPa was used to determine fibrosis, and the Index of Multiple Deprivation (IMD) was used to determine deprivation at the individual and neighborhood level.
resultsIn all, 325 (20.1%) patients had LSM ≥8.0 kPa. Fibrosis detection increased with the number of risk factors [2: OR 2.47 (p=0.027, 95% CI 1.11-5.50), 3: OR 5.19 (p <0.001, 95% CI 2.34-11.53), 4: OR 10.19 (p <0.001, 95% CI 4.44-23.40), 5: OR 23.40 (p <0.001, 95% CI 6.15-89.04)]. Patients with a low IMD score (<10) had significantly lower median LSMs than those with a high IMD score (>50) [5.4 kPa vs. 6.0 kPa (p=0.0005)]. In the proactive case finding pathway, obesity prevalence was higher in PCPs in areas of high deprivation [83.5% vs. 65.6% (p=0.003)]. Fibrosis detection was significantly higher in PCPs situated in neighborhoods with high socioeconomic deprivation compared with low deprivation [27.0% vs. 8.6% (p=0.028)].
conclusionLiver fibrosis detection was disproportionately higher in neighborhoods with greater socioeconomic deprivation. Screening strategies targeting areas with higher deprivation could increase the diagnostic yield of advanced fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.